Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells

Pier Luigi Tazzari, Giovanna Tabellini, Francesca Ricci, Veronica Papa, Roberta Bortul, Francesca Chiarini, Camilla Evangelisti, Giovanni Martinelli, Andrea Bontadini, Lucio Cocco, James A. McCubrey, Alberto M. Martelli

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such a combination is that perifosine was recently described to increase TRAIL-R2 receptor expression and decrease the cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53. Perifosine, at concentrations below IC50, dephosphorylated Akt and increased TRAIL-R2 levels, as shown by Western blot, reverse transcription-PCR, and flow cytometric analysis. Perifosine also decreased the long isoform of cFLIP (cFLIP-L) and the X-linked inhibitor of apoptosis protein (XIAP) expression. Perifosine and TRAIL synergized to activate caspase-8 and induce apoptosis, which was blocked by a caspase-8-selective inhibitor. Up-regulation of TRAIL-R2 expression was dependent on a protein kinase Cα/c-Jun-NH 2-kinase 2/c-Jun signaling pathway activated by perifosine through reactive oxygen species production. Perifosine also synergized with TRAIL in primary AML cells displaying constitutive activation of the Akt pathway by inducing apoptosis, Akt dephosphorylation, TRAIL-R2 upregulation, cFLIP-L and XIAP down-regulation, and c-Jun phosphorylation. The combined treatment negatively affected the clonogenic activity of CD34+ cells from patients with AML. In contrast, CD34+ cells from healthy donors were resistant to perifosine and TRAIL treatment. Our findings suggest that the combination of perifosine and TRAIL might offer a novel therapeutic strategy for AML.

Original languageEnglish
Pages (from-to)9394-9403
Number of pages10
JournalCancer Research
Volume68
Issue number22
DOIs
Publication statusPublished - Nov 15 2008

Fingerprint

Acute Myeloid Leukemia
CASP8 and FADD-Like Apoptosis Regulating Protein
X-Linked Inhibitor of Apoptosis Protein
Phosphatidylinositol 3-Kinase
Apoptosis
Caspase 8
Up-Regulation
Mitogen-Activated Protein Kinase 9
perifosine
TNF-Related Apoptosis-Inducing Ligand Receptors
Cell Line
Protein Kinase C
Inhibitory Concentration 50
Reverse Transcription
Reactive Oxygen Species
Lung Neoplasms
Protein Isoforms
Cell Death
Therapeutics
Down-Regulation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tazzari, P. L., Tabellini, G., Ricci, F., Papa, V., Bortul, R., Chiarini, F., ... Martelli, A. M. (2008). Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Research, 68(22), 9394-9403. https://doi.org/10.1158/0008-5472.CAN-08-2815

Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. / Tazzari, Pier Luigi; Tabellini, Giovanna; Ricci, Francesca; Papa, Veronica; Bortul, Roberta; Chiarini, Francesca; Evangelisti, Camilla; Martinelli, Giovanni; Bontadini, Andrea; Cocco, Lucio; McCubrey, James A.; Martelli, Alberto M.

In: Cancer Research, Vol. 68, No. 22, 15.11.2008, p. 9394-9403.

Research output: Contribution to journalArticle

Tazzari, PL, Tabellini, G, Ricci, F, Papa, V, Bortul, R, Chiarini, F, Evangelisti, C, Martinelli, G, Bontadini, A, Cocco, L, McCubrey, JA & Martelli, AM 2008, 'Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells', Cancer Research, vol. 68, no. 22, pp. 9394-9403. https://doi.org/10.1158/0008-5472.CAN-08-2815
Tazzari, Pier Luigi ; Tabellini, Giovanna ; Ricci, Francesca ; Papa, Veronica ; Bortul, Roberta ; Chiarini, Francesca ; Evangelisti, Camilla ; Martinelli, Giovanni ; Bontadini, Andrea ; Cocco, Lucio ; McCubrey, James A. ; Martelli, Alberto M. / Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells. In: Cancer Research. 2008 ; Vol. 68, No. 22. pp. 9394-9403.
@article{7dc6e57929a34704b246628eea7f703f,
title = "Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells",
abstract = "To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such a combination is that perifosine was recently described to increase TRAIL-R2 receptor expression and decrease the cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53. Perifosine, at concentrations below IC50, dephosphorylated Akt and increased TRAIL-R2 levels, as shown by Western blot, reverse transcription-PCR, and flow cytometric analysis. Perifosine also decreased the long isoform of cFLIP (cFLIP-L) and the X-linked inhibitor of apoptosis protein (XIAP) expression. Perifosine and TRAIL synergized to activate caspase-8 and induce apoptosis, which was blocked by a caspase-8-selective inhibitor. Up-regulation of TRAIL-R2 expression was dependent on a protein kinase Cα/c-Jun-NH 2-kinase 2/c-Jun signaling pathway activated by perifosine through reactive oxygen species production. Perifosine also synergized with TRAIL in primary AML cells displaying constitutive activation of the Akt pathway by inducing apoptosis, Akt dephosphorylation, TRAIL-R2 upregulation, cFLIP-L and XIAP down-regulation, and c-Jun phosphorylation. The combined treatment negatively affected the clonogenic activity of CD34+ cells from patients with AML. In contrast, CD34+ cells from healthy donors were resistant to perifosine and TRAIL treatment. Our findings suggest that the combination of perifosine and TRAIL might offer a novel therapeutic strategy for AML.",
author = "Tazzari, {Pier Luigi} and Giovanna Tabellini and Francesca Ricci and Veronica Papa and Roberta Bortul and Francesca Chiarini and Camilla Evangelisti and Giovanni Martinelli and Andrea Bontadini and Lucio Cocco and McCubrey, {James A.} and Martelli, {Alberto M.}",
year = "2008",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-08-2815",
language = "English",
volume = "68",
pages = "9394--9403",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor perifosine in acute myelogenous leukemia cells

AU - Tazzari, Pier Luigi

AU - Tabellini, Giovanna

AU - Ricci, Francesca

AU - Papa, Veronica

AU - Bortul, Roberta

AU - Chiarini, Francesca

AU - Evangelisti, Camilla

AU - Martinelli, Giovanni

AU - Bontadini, Andrea

AU - Cocco, Lucio

AU - McCubrey, James A.

AU - Martelli, Alberto M.

PY - 2008/11/15

Y1 - 2008/11/15

N2 - To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such a combination is that perifosine was recently described to increase TRAIL-R2 receptor expression and decrease the cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53. Perifosine, at concentrations below IC50, dephosphorylated Akt and increased TRAIL-R2 levels, as shown by Western blot, reverse transcription-PCR, and flow cytometric analysis. Perifosine also decreased the long isoform of cFLIP (cFLIP-L) and the X-linked inhibitor of apoptosis protein (XIAP) expression. Perifosine and TRAIL synergized to activate caspase-8 and induce apoptosis, which was blocked by a caspase-8-selective inhibitor. Up-regulation of TRAIL-R2 expression was dependent on a protein kinase Cα/c-Jun-NH 2-kinase 2/c-Jun signaling pathway activated by perifosine through reactive oxygen species production. Perifosine also synergized with TRAIL in primary AML cells displaying constitutive activation of the Akt pathway by inducing apoptosis, Akt dephosphorylation, TRAIL-R2 upregulation, cFLIP-L and XIAP down-regulation, and c-Jun phosphorylation. The combined treatment negatively affected the clonogenic activity of CD34+ cells from patients with AML. In contrast, CD34+ cells from healthy donors were resistant to perifosine and TRAIL treatment. Our findings suggest that the combination of perifosine and TRAIL might offer a novel therapeutic strategy for AML.

AB - To potentiate the response of acute myelogenous leukemia (AML) cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity, we have examined the efficacy of a combination with perifosine, a novel phosphatidylinositol-3-kinase (PI3K)/Akt signaling inhibitor. The rationale for using such a combination is that perifosine was recently described to increase TRAIL-R2 receptor expression and decrease the cellular FLICE-inhibitory protein (cFLIP) in human lung cancer cell lines. Perifosine and TRAIL both induced cell death by apoptosis in the THP-1 AML cell line, which is characterized by constitutive PI3K/Akt activation, but lacks functional p53. Perifosine, at concentrations below IC50, dephosphorylated Akt and increased TRAIL-R2 levels, as shown by Western blot, reverse transcription-PCR, and flow cytometric analysis. Perifosine also decreased the long isoform of cFLIP (cFLIP-L) and the X-linked inhibitor of apoptosis protein (XIAP) expression. Perifosine and TRAIL synergized to activate caspase-8 and induce apoptosis, which was blocked by a caspase-8-selective inhibitor. Up-regulation of TRAIL-R2 expression was dependent on a protein kinase Cα/c-Jun-NH 2-kinase 2/c-Jun signaling pathway activated by perifosine through reactive oxygen species production. Perifosine also synergized with TRAIL in primary AML cells displaying constitutive activation of the Akt pathway by inducing apoptosis, Akt dephosphorylation, TRAIL-R2 upregulation, cFLIP-L and XIAP down-regulation, and c-Jun phosphorylation. The combined treatment negatively affected the clonogenic activity of CD34+ cells from patients with AML. In contrast, CD34+ cells from healthy donors were resistant to perifosine and TRAIL treatment. Our findings suggest that the combination of perifosine and TRAIL might offer a novel therapeutic strategy for AML.

UR - http://www.scopus.com/inward/record.url?scp=56449084185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56449084185&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-2815

DO - 10.1158/0008-5472.CAN-08-2815

M3 - Article

C2 - 19010914

AN - SCOPUS:56449084185

VL - 68

SP - 9394

EP - 9403

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 22

ER -